About this Research Topic
Modern pharmaceuticals have been developed from small molecules extracted from natural resources. Galantamine, a cholinesterase inhibitor is a classic example of the discovery of small molecules for neuroprotection. This example, among others, demonstrates that natural products may represent an important pool for generating novel therapeutics. Despite of the opportunities they provide, several challenges are also associated with the process of natural product-based drug discovery, such as technical limitations in the isolation, characterization, screening, and optimization.
In this Research Topic, we aim to outline the advancement in the use of various natural products as possible treatments against various neurological and neurodegenerative disorders like Parkinson's disease (PD), Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS). We also encourage colleagues working in the field of traditional medicine systems to submit their research.
We seek Original Research, Reviews, Mini-Reviews, Hypotheses and Theories, Perspectives, Clinical Trials, Case Reports and Opinion articles that cover, but are not limited to, the following topics:
- Identification of molecular targets for natural products in neuroprotection.
- Integrating bioactivity-guided approaches in understanding the molecular mechanisms of various neurological and neurodegenerative diseases.
- Mechanistic attributes of bioactive natural products against various neurological pathways.
- Preclinical and clinical studies pertaining to natural products and traditional medicine including Ayurveda, TCM and Kampoo etc.
Keywords: Bioactivity, metabolomics, molecular targets, natural products, neurodegeneration
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.